Pharmaceuticals

BGM released FY2025 Q1 earnings on July 24 (EST), actual revenue USD 7.156 M, actual EPS USD -0.015

BGM released FY2025 Q2 earnings on July 24 Pre-Market (EST), actual revenue USD 7.156 M, actual EPS USD -0.015

BGM released FY2025 Semi-Annual Earnings on July 24 Pre-Market (EST), actual revenue USD 14.31 M, actual EPS USD -0.03

BGM released FY2024 Annual Earnings on January 27 (EST), with actual revenue of 25.1 M USD and EPS of -0.2 USD

BGM released FY2024 Q2 earnings on August 14 (EST), actual revenue USD 6.281 M, actual EPS USD 0.0286

BGM released FY2024 Q1 earnings on August 14 (EST), actual revenue USD 6.281 M, actual EPS USD 0.0286

BGM released FY2024 Semi-Annual earnings on August 14 (EST), actual revenue USD 12.56 M, actual EPS USD 0.0573

BGM released FY2022 annual earnings on February 15, 2024 (EST), with actual revenue of 64.86 M USD and EPS of 0.1489 USD

BGM released FY2023 annual earnings on February 15 (EST), with actual revenue of 46.47 M USD and EPS of -1.0799 USD

Urban-Gro

Mangoceuticals

The Gabelli Equity Trust Inc.

bioAffinity Tech

Jianzhi Edu Tech

Lichen

Zhengye Biotechnology

Actelis Networks

Quantum Biopharma

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap

BGM(BGM.US)

BGM Stock Performance Chart